Department of Infection, Inflammation and Immunity, Institute of Lung Health, University of Leicester, Leicester, UK.
Curr Opin Pulm Med. 2011 Jan;17(1):16-22. doi: 10.1097/MCP.0b013e3283410acd.
asthma exacerbations occur unpredictably, are a cause of morbidity and mortality, and contribute significantly to increased healthcare costs. Inhaled corticosteroids reduce exacerbations and improve quality of life.
the aetiopathology of asthma exacerbations is heterogeneous. Attempts to phenotype the heterogeneity of the pattern of airway inflammation by noninvasive monitoring of airway inflammation has identified a subgroup of patients with eosinophilic inflammation who are most likely to respond to steroid therapy. Strategies directed to normalize eosinophilic airway inflammation with corticosteroids have consistently led to a marked reduction in exacerbations. In contrast, their role in modulating the natural history of disease is less certain.
in the near future, improvements in our understanding of the mechanisms of exacerbations may identify therapeutic targets. While we await these developments, inhaled corticosteroids remain the first choice anti-inflammatory therapy for asthma.
哮喘发作不可预测,是发病率和死亡率的一个原因,并显著增加医疗保健成本。吸入皮质类固醇可减少发作并提高生活质量。
哮喘发作的病因学是异质的。通过非侵入性监测气道炎症来表型气道炎症模式的异质性,已经确定了一组嗜酸性粒细胞炎症的患者,他们最有可能对类固醇治疗有反应。用皮质类固醇使嗜酸性粒细胞气道炎症正常化的策略始终导致发作明显减少。相比之下,它们在调节疾病自然史中的作用还不太确定。
在不久的将来,对发作机制的理解的提高可能会确定治疗靶点。在我们等待这些进展的同时,吸入皮质类固醇仍然是哮喘的首选抗炎治疗。